Havent been following the story for a while. With management and board changes and cardio protection a now a big focus the FTO inhibition story is less visible to me. Can i tempt anyone to explain whether the lab/clinical trial process remains on track. Melanoma was an early target. As a bit of a tease: when i first started looking at this stock it showed promise as a cancer treatment of equal standing to standard of care in some setting but noted as being less damaging to heart. then that got de-emphasised as the FTO discovery took centre stage. Now the focus is cardio protection which feels more like the original story. I understand that cardio-protection could have broad application. But before cardio protection Wombat et al were talking about a drug that was bigger than Keytruda. Has the FTO opportunity been downgarded, pushed out delayed, seem less likely of scusses then a year ago. Has anything changed?
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-2364
-
-
- There are more pages in this discussion • 626 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $276.0M |
Open | High | Low | Value | Volume |
$1.69 | $1.69 | $1.55 | $456.4K | 284.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $1.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.62 | 2659 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 1.585 |
2 | 3324 | 1.560 |
3 | 3669 | 1.550 |
1 | 339 | 1.545 |
1 | 400 | 1.540 |
Price($) | Vol. | No. |
---|---|---|
1.620 | 2659 | 1 |
1.650 | 1000 | 1 |
1.680 | 1830 | 1 |
1.690 | 15707 | 4 |
1.750 | 30400 | 2 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online